Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Genomic, Epigenomic, and Transcriptomic Landscapes of Brain Cancers
share announcement

Genomic, Epigenomic, and Transcriptomic Landscapes of Brain Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 603

Special Issue Editors

Dr. Shota Tanaka

E-Mail Website
Guest Editor
Department of Neurosurgery, The University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan
Interests: brain tumor; malignant brain tumor; glioma; glioblastoma; ependymoma; experimental brain surgery; personalized medicine; tailor-made medicine; gene diagnosis; molecular diagnosis of cancer; signal transduction; molecularly targeted therapy; cancer stem cell; molecular imaging; cancer nursing
Dr. Joseph Papamatheakis

E-Mail Website
Guest Editor
Institute of Molecular Biology and Biotechnology of the Foundation for Research and Technology Hellas, Heraklion, Greece
Interests: brain; tumor microenvironment; bioactive compounds; molecular oncology immunology gene expression

Special Issue Information

Dear Colleagues,

Epigenetic changes play a significant role in how genes are turned on or off in cancer cells, thus modulating their behavior. Shedding light on the molecular signatures associated with different subtypes of brain tumors has the potential to impact the field of brain cancer research. Moreover, precision medicine, which targets the mutations based on cancer multi-gene panel testing, can be performed for a similar purpose. Better knowledge and understanding of the genetics, epidemiology and transcriptomic landscapes might further advance our understanding of the underlying genetic and molecular factors driving brain cancer pathogenesis, opening new avenues for improving patient outcomes and advancing therapeutic approaches.

Therefore, we are pleased to invite you to submit your papers to this Special Issue, which will highlight the genomic, epigenomic, and transcriptomic landscapes of brain cancers. In this Special Issue, original research articles and reviews are welcome, along with expert opinions, systematic reviews and meta-analyses.

We look forward to receiving your contributions.

Dr. Shota Tanaka
Dr. Joseph Papamatheakis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genomic
  • epigenomic
  • transcriptomic
  • glioma
  • brain tumor
  • glioblastoma
  • medulloblastoma

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

12 pages, 3456 KiB  
Review
Diffuse Gliomas with FGFR3::TACC3 Fusion: Morphological and Molecular Features and Classification Challenges
by Elena Marastoni, Davide Mulone and Valeria Barresi
Cancers 2024, 16(9), 1644; https://doi.org/10.3390/cancers16091644 - 25 Apr 2024
Viewed by 453
Abstract
FGFR3::TACC3 fusion is a driver, potentially targetable, genetic alteration identified in approximately 4% of high-grade diffuse gliomas and rare cases with low-grade histology. Herein, we review the genetic and epigenetic features of these tumors and highlight the challenges in their classification [...] Read more.
FGFR3::TACC3 fusion is a driver, potentially targetable, genetic alteration identified in approximately 4% of high-grade diffuse gliomas and rare cases with low-grade histology. Herein, we review the genetic and epigenetic features of these tumors and highlight the challenges in their classification and grading. Diffuse gliomas with FGFR3::TACC3 fusion display unique histopathological and molecular features, including an oligodendroglioma-like appearance, calcifications, and CD34 extravascular immunoreactivity. High-grade tumors exhibit molecular alterations and a DNA methylation profile typical of glioblastoma, suggesting that they may represent a subtype clinically characterized by a slightly better prognosis. Tumors with low-grade morphology are genetically and epigenetically heterogeneous. Some, exclusive to adults, have molecular alterations typical of glioblastoma, although most do not match any methylation classes, using version 12.5 of the Heidelberg classifier. Another group, which mostly affects children or adolescents, lacks the molecular features of glioblastoma and has a DNA methylation profile similar to that of low-grade glioneuronal tumors. In conclusion, diffuse gliomas with FGFR3::TACC3 fusion do not constitute a distinct nosological entity, owing to their genetic and epigenetic diversity. Further studies are warranted to clarify the biological aggressiveness of tumors with low-grade histology to refine the grading and determine the optimal treatment strategy. Full article
(This article belongs to the Special Issue Genomic, Epigenomic, and Transcriptomic Landscapes of Brain Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop